Mosunetuzumab is a first-in-class CD20×CD3 T-cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells, thereby redirecting the patient's T cells to release cytotoxic proteins and eliminate B cells. It has received conditional marketing authorization in the European Union for the treatment of follicular lymphoma (FL) in patients who have received at least two prior lines of systemic therapy.